GLP-1 medicines sit at the centre of the fastest-growing telehealth category in the world, and operators now want to bring the model to the UAE. The legal question comes first. This explainer sets out how GLP-1s are sold lawfully through telehealth in Dubai, and what the licensed structure behind a compliant operation looks like.
Are GLP-1s legal to sell online in the UAE?
Yes. GLP-1s can be sold online in the UAE as prescription medicines, through a DHA-licensed telehealth operation in which a licensed clinician consults the patient, issues the prescription, and licensed channels dispense and deliver the medicine. What is never permitted is direct-to-consumer supply without a prescription.
The structure matters because telehealth in Dubai is a regulated clinical service, not an app. The Dubai Health Authority (DHA) licenses telehealth through its Sheryan portal, and the service operates under the DHA Telehealth Standards. Remote prescribing is permitted within those standards, with specific rules and restrictions, particularly for controlled medicines. A GLP-1 sale is therefore the end of a clinical process: consultation, prescription, dispensing, delivery.
One caution before the detail. GLP-1 is a category, not a legal status. Whether a specific product can be supplied depends on that product's own position with the Emirates Drug Establishment (EDE): registered, supplied through a compliant compounding pathway, or not yet eligible. We treat the product question and the licensing question as two separate workstreams, because they are.
What the law requires end to end
A compliant GLP-1 telehealth operation stands on five elements. Each one is licensed, inspectable, and named on paper.
A licensed facility
The operating entity holds a DHA facility licence, obtained through the Sheryan portal, covering telehealth activity. The premises, policies, and records behind the service form part of that licence.
A licensed prescriber consultation
DHA-licensed clinicians consult each patient remotely and record the encounter in an EMR connected to NABIDH, the DHA health information exchange.
A prescription
Supply follows a prescription issued by the clinician after the consultation. There is no compliant version of this model that skips this step.
Licensed dispensing and delivery
The medicine is dispensed and delivered through licensed channels. The consumer brand sits in front; licensed pharmacy fulfilment sits behind it.
A lawful product
The GLP-1 itself is either a registered product or supplied through a compliant compounding pathway with partner labs. Product status is confirmed before the service offers it.
Where operators go wrong
The failures we see are structural, and they cluster in two places.
The first is unlicensed importation. Under UAE law, only entities holding a pharmaceutical facility or medical warehouse licence, with the corresponding EDE import permit, may import pharmaceutical products. A GLP-1 shipment outside that framework has no legal route into the country, and unregistered importation risks seizure and penalties. Buying stock abroad and couriering it in is not a shortcut; it is the exposure.
The second is marketing that skips the prescription step. A checkout flow that treats a prescription medicine like an ordinary consumer product is not compliant, however polished the site looks. The compliant model always places the consultation and the prescription before supply, and the DHA Telehealth Standards set the rules that consultation must meet.
The compliant supply chain behind fulfilment
Behind every compliant GLP-1 telehealth business is a pharmaceutical supply chain the patient never sees. It runs on licences.
What sits behind GLP-1 fulfilment
- Importer credentials: a licensed pharmaceutical facility or medical warehouse holds the right to import
- EDE import permits covering each shipment before it moves
- Cold chain handling from the manufacturing site to the point of dispensing, with the temperature record held under GDP in a licensed warehouse
- Partner compounding labs where the model uses compliant compounded preparations
- Distribution to licensed facilities only, never direct from a foreign supplier
GLP-1 and most peptide therapeutics are temperature sensitive, so the cold chain is not an optional upgrade; it is part of the product's lawful handling. We cover the product side of this route, from EDE classification through import permits to GDP warehousing, on our peptide import and registration page.
How to launch this as a business
The licensing, the clinical team, and the supply chain can be built as one project. Our turnkey telemedicine build delivers the entity and trade licence, the DHA facility licence through Sheryan, compliant premises, a NABIDH-connected EMR taken through Go-Live, DHA-licensed clinicians engaged under a zero-payroll model, and the pharmacy and logistics arrangements behind fulfilment.
A build of this kind typically reaches an active DHA licence in approximately 45 to 60 days from signature, subject to authority response times, and is delivered under one fixed, all-inclusive quote. For the licensing sequence step by step, see our guide to starting a telemedicine business in the UAE.
See the turnkey telemedicine build
Frequently asked questions
Can GLP-1s be sold online in the UAE without a prescription?
Who regulates a GLP-1 telehealth service in Dubai?
Can clinicians prescribe GLP-1s remotely in the UAE?
Do GLP-1 products need cold chain handling?
How long does it take to launch a compliant GLP-1 telehealth business?
This explainer is general information for operators and investors, not regulatory, legal, or medical advice. Prescription medicines are prescribed by licensed clinicians after consultation. Confirm current requirements with the relevant authority or your regulatory partner before acting.